{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-024920","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.877218+00:00","generated_at":"2026-06-01T09:09:52.485998+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Avalo Therapeutics receives Nasdaq delisting notice for negative stockholders' equity of $112.6M","bullets":["Reported stockholders' equity of negative $112.6M in Q1 2024 10-Q, below $2.5M minimum.","Has 45 days (until July 5, 2024) to submit a compliance plan to Nasdaq Staff.","If plan accepted, Staff may grant up to 180-day extension to regain compliance.","No immediate effect on listing; common stock continues trading on Nasdaq under AVTX.","Company evaluating options; no assurance of regaining compliance or avoiding delisting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-024920","json":"https://secwatch.observer/filing/0001628280-24-024920.json","markdown":"https://secwatch.observer/filing/0001628280-24-024920.md","text":"https://secwatch.observer/filing/0001628280-24-024920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024024920/0001628280-24-024920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024024920/avtx-20240520.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:09:52.485998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}